Marinus Pharmaceuticals, Inc. (MRNS) 

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Show less

Over the last 12 months, insiders at Marinus Pharmaceuticals, Inc. have bought $0 and sold $374,962 worth of Marinus Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Marinus Pharmaceuticals, Inc. have bought $125,000 and sold $296,042 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $125,000 was made by Braunstein Scott (Chief Executive Officer) on 2019‑12‑13.